Diagnostic performance of sentinel lymphnode mapping algorithm in early stageendometrial cancer.

Department of Atomic Energy- CTC0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年4月3日

试验速览

暂无简介。

•1)Patients who are between 18 â?? 80 yrs of age.
•2)Patients with clinical and/or radiological stage I or II carcinoma endometrium.
•3)Patients who are planned for primary surgical staging (open /MIS) at TMH/ACTREC.
•4) Patients who have a preoperative pathology proof of carcinoma endometrium in the form of endometrial biopsy which has been either done in TMH/ACTREC or has undergone pathological review at TMH/ACTREC
•5) Patients with any histological subtype (endometrioid, serous, clear cell, carcinosarcoma).
•6) Patients with any histological grade.

•1) Patients who do not consent for the procedure.
•2) Uterine confined, low risk endometrial cancer patients with T max size <2 cm, low grade (grade I/II), with no / minimal superficial myoinvasion will be excluded from the study since as per the current institutional protocol, lymphnode staging is omitted in these cases.
•3) Patients with locally advanced disease/ enlarged or suspicious lymph nodes/ intra-abdominal/ distant metastasis on pre-operative or intra-operative assessment.
•4) Patients with previous surgeries/ procedures impairing lymphatic drainage (myomectomy/ retroperitoneal surgery/ abdominopelvic radiotherapy).
•5) Patients with known allergy to iodine.
•6) Patients with liver disease.
•7) Patients with pre-existing lymphedema

发起方

Department of Atomic Energy- CTC